Subscribe to RSS
DOI: 10.1055/s-2005-863076
© Georg Thieme Verlag Stuttgart · New York
Pneumokokken-Schutzimpfung bei obstruktiven Lungenerkrankungen - Was können wir erwarten?
Pneumococcal vaccination in obstructive airway diseases - what can we expect?Publication History
eingereicht: 29.10.2004
akzeptiert: 18.2.2005
Publication Date:
24 February 2005 (online)

Zusammenfassung
Die Leitlinien vieler Länder empfehlen Pneumokokken-Schutzimpfungen für Patienten mit obstruktiven Lungenkrankheiten. Diese Arbeit gibt eine Übersicht zur Immunogenität und Sicherheit dieser Maßnahme. Es gibt keine Evidenz für eine nennenswerte Beeinträchtigung oder Gefährdung dieser Patienten durch eine Pneumokokken-Schutzimpfung. Wenige Arbeiten haben sich mit der Bedeutung der Pneumokokken-Schutzimpfung für die Vermeidung von Exazerbationen obstruktiver Lungenkrankheiten befasst. Vorhandene Studien haben diese Fragestellung meist nur als Nebenaspekt untersucht. Die Ergebnisse sind im Kindes- wie Erwachsenenalter imkohärent. Da jedoch die Konjugatvakzine Kinder unter 5 Jahren zusätzlich effektiv vor lebensbedrohlichen invasiven Infektionen schützt, und bei gesunden Erwachsenen bakteriämischen Pneumonien durch die Polysaccharidvakzine vorgebeugt wird, erscheint der Einsatz bei chronisch lungenkranken Patienten gerechtfertigt.
Summary
Many countries’ guidelines recommend pneumococcal vaccination for patients suffering from obstructive airway disease. This paper reviews the literature as to immunogenicity and safety of this immunization. There is no evidence for a negative effect of pneumococcal vaccination on these patients. Only a few data exist on the preventive impact of pneumococcal vaccination as to exacerbations of obstructive airway diseases. Existing studies mostly took up this question as a side aspect. The effect in children and adults appears limited. On the other hand, the pneumococcal conjugate vaccine prevents life-threatening invasive infections in children younger than 5 years, and pneumococcal polysaccharide vaccine protects healthy adults against bacteriaemic pneumonia. Thus, pneumococcal vaccination of patients suffering from obstructive airway disease is recommendable.
Literatur
- 1
Black S, Shinefield H, Fireman B. et al. Northern California Kaiser Permanente Vaccine Study Center Group .
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine
in children.
Pediatr Infect Dis J.
2000;
19
187-195
MissingFormLabel
- 2
Black S, Shinefield H.
Safety and efficacy of the seven valent pneumococcal conjugate vaccine: evidence from
Northern California.
Eur J Pediatr.
2002;
161
127-131
MissingFormLabel
- 3
Black S B, Shinefield H R, Ling S. et al .
Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than
five years of age for prevention of pneumonia.
Pediatr Inf Dis J.
2002;
21
810-815
MissingFormLabel
- 4
Bogaert D, van der Valk P, Ramdin R. et al .
Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive
pulmonary disease.
Infect Immun.
2004;
72
818-823
MissingFormLabel
- 5
Christensen B, Hedlund J, Lundberg P, Ortqvist A.
Additive preventive effect of influenza and pneumococcal vaccines in elderly persons.
Eur Respir J.
2004;
23
363-368
MissingFormLabel
- 6
Dagan R, Givon-Lavi N, Zamir O, Fraser D.
Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus
pneumoniae in day-care centers.
Pediatric Infect Dis J.
2003;
22
532-540
MissingFormLabel
- 7
Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P.
Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization
with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria
toxoid.
Pediatr Infect Dis J.
1997;
16
1060-1064
MissingFormLabel
- 8
Davies L, Hardcroft Mutton K, Earis J E, Kennedy N J.
Antimicrobial management of acute exacerbation of chronic airflow limitation.
QJM.
2001;
94
373-378
MissingFormLabel
- 9
Davis L D, Fireman B, Shinefield H R.
Pneumococcal Conjugate Vaccine in Children.
NEJM.
2004;
350
84-85
MissingFormLabel
- 10 De Roux A, Schmidt N, Rose M, Zielen S, Pletz M, Lode H. Immunogenity of the 23-valent Pneumococcal Polysaccharide Vaccine in COPD Patients. 2004 akzeptiert für respiratory medicine
MissingFormLabel
- 11 EMEA .Commission Decision amending the marketing authorization for the medicinal product
for human use „Prevenar - Pneumococcal saccharide conjugated vaccine, adsorbed”,. EU/1/00/167/001 - 007, (EMEA/H/C/323/II/18) Var 18 type II 2004
MissingFormLabel
- 12
Evans H E, Mandel I, Glass L.
Serum enzyme inhibitors, immunoglobulins, and upper respiratory tract bacteria in
asthma.
Am Rev Respir Dis.
1973;
108
672-675
MissingFormLabel
- 13
Fine M J, Smith M A, Carson C A. et al .
Efficacy of pneumococcal vaccination in adults.
Arch Intern Med.
1994;
154
2666-2677
MissingFormLabel
- 14
Fletcher T J, Tunnicliffe W S, Hammond K, Roberts K, Ayres J G.
Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine
in patients with chronic respiratory disease.
BMJ.
1997;
314
1663-1666
MissingFormLabel
- 15
Gratten M, Morey F, Dixon J. et al .
An outbreak of serotype 1 Streptococcus pneumoniae infection in central Australia.
Med J Aust.
1993;
158
340-342
MissingFormLabel
- 16
Haby M M, Peat J K, Marks G B, Woolcock A J, Leeder S R.
Asthma in preschool children: prevalence and risk factors.
Thorax.
2001;
56
589-595
MissingFormLabel
- 17
Hausdorff W P, Bryant J, Kloek C, Paradiso P R, Siber G R.
The contribution of specific pneumococcal serogroups to different disease manifestations:
implications for conjugate vaccine formulation and use.
Clin Infect Dis.
2000;
30
100-140
MissingFormLabel
- 18
Hess T.
Pneumococcal vaccination: yes or no?.
Schweiz Med Wochenschr.
1998;
128
1096-1103
MissingFormLabel
- 19
ISAAC .
The international study of asthma and allergies in childhood Steering Committee. Worldwide
variation in prevalence of asthma, allergic rhinoconjunctivitis, and atopic eczema.
Lancet.
1998;
351
1225-1232
MissingFormLabel
- 20
Klugman K P, Madhi S A, Huebner R E, Kohberger R, Mbelle N, Pierce N.
A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without
HIV infection.
NEJM.
2003;
349
1341-1348
MissingFormLabel
- 21
Lahhod N, Emerson S S, Kumar P, Sorensen R U.
Antibiotic levels and response to pneumococcal vaccine in steroid-dependent asthma.
Ann Allergy.
1993;
70
289-294
MissingFormLabel
- 22
Lee H J, Kang J H, Henrichsen J. et al .
Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in healthy
children and children at increased risk of pneumococcal infection.
Vaccine.
1995;
13
1533-1538
MissingFormLabel
- 23
Lehmann D, Marshall T F, Riley I D, Alpers M P.
Effect of pneumococcal vaccine on morbidity from acute lower respiratory tract infections
in Papua New Guinean children.
Ann Trop Paediatr.
1991;
11
247-257
MissingFormLabel
- 24
Madhi S A, Klugman K P.
A role for Streptococcus pneumoniae in virus-associated pneumonia.
Nature Medicine.
2004;
10
811-813
MissingFormLabel
- 25
Marfan A A, Sporrer J, Moore P S, Siefkin A D.
Risk factors for adverse outcomes in persons with pneumococcal pneumonia.
Chest.
1995;
107
457-462
MissingFormLabel
- 26
Mbelle N, Huebner R E, Wasas A D, Kimura A, Chang I, Klugman K P.
Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal
conjugate vaccine.
J Infect Dis.
1999;
180
1171-1176
MissingFormLabel
- 27
Melegaro A, Edmunds J.
The 23-valent pneumococcal polysaccharide vaccine: Part I. Efficacy of PPV in the
elderly: A comparison of meta-analyses.
Europ J Epidemiol.
2004;
19
353-363
MissingFormLabel
- 28
Moore R A, Wiffen P J, Lipsky B A.
Are the pneumococcal polysaccharide vaccines effective? Meta analysis of the prospective
trials.
BMC Family Practice.
2000;
1
1471-2296
MissingFormLabel
- 29
Obaro S, Adegbola R A, Banya W A, Greenwood B M.
Carriage of pneumococci after pneumococcal vaccination.
Lancet.
1996;
348
271-272
MissingFormLabel
- 30
Obaro S, Adegbola R.
The pneumococcus: carriage, disease and conjugate vaccines.
J Med Microbiol.
2002;
51
98-104
MissingFormLabel
- 31
O’Brien K L, Swift A J, Winkelstein J A. et al. Pneumococcal Conjugate Vaccine Study Group .
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197)
among infants with sickle cell disease.
Pediatrics.
2000;
106
965-972
MissingFormLabel
- 32
Pelton S I, Klein J O.
The future of pneumococcal conjugate vaccines for prevention of pneumococcal diseases
in infants and children.
Pediatrics.
2002;
110
805-814
MissingFormLabel
- 33
Reinert R R, Kaufhold A, Schlaeger J J, Meschery V, Lütticken R.
Serotype distribution and antibiotic susceptibility of Streptococcus pneumoniae isolates
causing systemic infections among children in Germany, 1992 to 1996.
Pediatr Infect Dis J.
1997;
16
244-245
MissingFormLabel
- 34
Riley I D, Lehmann D, Alpers M P, Marshall T F, Gratten H, Smith D.
Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections
in Papua New Guinean children.
Lancet.
1986;
2
877-881
MissingFormLabel
- 35
Rose M, Hey C, Kujumdshiev S, Gall V, Schubert R, Zielen S.
Immunogenicity of pneumococcal vaccination of patients with cochlear implants.
J Infect Dis.
2004;
190
551-557
MissingFormLabel
- 36
Rose M, Hey C, Kujumdshiew S, Gall V, Zielen S.
Gefahr der bakteriellen Meningitis.
Dtsch Ärztebl.
2004;
101
1072-1074
MissingFormLabel
- 37
Schuller N.
Prophylaxis of otitis media in asthmatic children.
Pediatr Infect Dis.
1983;
2
280-283
MissingFormLabel
- 38
STIKO .
Aktuelle Impfempfehlungen: Pneumokokken.
Epidemiol Bull.
2004;
MissingFormLabel
- 39
Vernacchio L, Neufeld E, MacDonald K.
Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent
pneumococcal vaccine in children and young aduls with sickle cell disease.
J Pediatr.
1998;
133
275-278
MissingFormLabel
- 40
von Kries R, Hermann M, Hachmeister A. et al .
Prediction of the potential benefit of different pneumococcal conjugate vaccines on
invasive pneumococcal disease in German children.
Pediatr Infect Dis J.
2002;
21
1017-1023
MissingFormLabel
- 41
Whitney C G, Klugman K P.
Vaccines as tools against resistance: the example of pneumococcal conjugate vaccine.
Semin Pediatr Infect Dis.
2004;
15
86-93
MissingFormLabel
- 42
WHO .
Pneumococcal vaccines.
Weekly Epidemiology Records.
1999;
74
177-183
MissingFormLabel
- 43
Worth H, Buhl R, Cegla U. et al .
Guidelines for the diagnosis and treatment of chronic obstructive bronchitis and pulmonary
emphysema issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für Pneumologie.
Pneumologie.
2002;
56
704-738
MissingFormLabel
- 44
Zielen S, Buhring I, Strnad N, Reichenbach J, Hofmann D.
Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders
to the 23-valent pneumococcal vaccine.
Infect Immun.
2000;
68
1435-1440
MissingFormLabel
- 45
Fiore A E, Levine O S, Elliott J A, Facklam R R, Butler J C.
Effectiveness of Pneumococcal Polysaccharide Vaccine for Preschool-Age Children with
Chronic Disease.
Energy Infect Dis.
1999;
5(6)
828-831
MissingFormLabel
Dr. med. Markus Rose
Zentrum der Kinderheilkunde und Jugendmedizin, Pneumologie und Allergologie, J. W.
Goethe Universität
Theodor-Stern-Kai 7
60590 Frankfurt am Main
Phone: 069/63015754
Email: Markus.Rose@kgu.de